AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Presentation (1999)
14 slides from AstraZeneca's investor presentation, 1999
Slide 1: Building our future
Building our future Claes Wilhelmsson Director, Research & Development First year – designing the AstraZeneca R&D future 1998 1999 1999 1999 Dec 9th Apr 6th Oct 14th Nov 30th Overall R&D Portfolio R&D strategy Implement organisation design review development plans
Slide 2: AstraZeneca - a mega-merger that is working
AstraZeneca - a mega-merger that is working Why the future looks promising h Well-suited partners h Savvy patent management h Promising pipeline h Strong growth Source: Business Week, November 15, 1999 Portfolio complementarity Astra Zeneca hThromboembolism hLipid lowering CV hArrhythmias hMetabolis
Slide 3: Portfolio complementarity
Portfolio complementarity Astra Zeneca hLocal and regional hGeneral anaesthesia Pain anaesthetics hDepression hSchizophrenia CNS hEpilepsy hParkinson´s disease hMigraine hMultiple sclerosis Portfolio complementarity Astra Zeneca hWorld leader in GI gastroenterology hWorld leader in hormonal Oncology
Slide 4: A strong portfolio today, a strong pipeline for tomorrow
A strong portfolio today Diprivan® Seroquel® Arimidex® Losec® Nolvadex® Casodex® Accolate® Tenormin® Oxis® Zoladex® Seloken® Atacand® Pulmicort® Zomig® Zestril® Xylocaine® Rhinocort® Merrem® Prilosec® Plendil® A strong pipeline for tomorrow h The merged pipeline – 159 projects – 57 New Chemical Enti
Slide 5: First year – designing the AstraZeneca R&D future
First year – designing the AstraZeneca R&D future 1998 1999 1999 1999 Dec 9th Apr 6th Oct 14th Nov 30th Overall R&D Portfolio R&D strategy Implement organisation design review development plans Principles h One R&D organisation managed globally h Critical mass to be leading in our chosen areas h Str
Slide 6: One R&D organisation managed globally
One R&D organisation managed globally Head of R&D Human R&D IOff Resources Finance R&D Adm. Intellectual R&D Property Committees Global R&D Global Global Discovery TAs Operations Development Team oriented and project-led organisation Product CD Develop- mainten. & Target Hit Lead Lead Concept Core p
Slide 7: Objectives: Building a leading force in Global Discovery
Objectives h Build a leading Discovery organisation h Increase R&D output and efficiency h Build US presence h Achieve scientific and technological critical mass h Build, develop and diversify our talent Building a leading force in Global Discovery h Improve candidate drug output and quality h Lead
Slide 8: Global Discovery actions
Global Discovery actions h Consolidate Research Areas to achieve critical mass h Enabling Science & Technology - create 3 centres of excellence h Safety Assessment - 2 GLP sites and 1 Discovery site h Reduce from 15 sites to 9 h Build in the USA h Build Informatics and Genetics h Major expansion in
Slide 9: Summary of Global Development actions; strong commitment to R&D
Summary of Global Development actions h Create a simple and effective global organisation h Create a stimulating, performance-linked culture for everyone h Use strategic sourcing to make best use of internal and external skills h Radically improve performance through world class information manageme
Slide 10: Future AstraZeneca R&D sites; output and efficiency targets
Future AstraZeneca R&D sites E H No M S A ´Ma L AvC Ab W P MoCa R Bu B WN O B 9 R&D sites 13 other locations R&D output and efficiency targets h Increase Candidate Drug (CD) output (>15/year) by 2003 h Double project success rate from CD to launch to 20% h Deliver three medically important, commerci
Slide 11: Rationale for TA driven organisation
Rationale for TA driven organisation h Disease orientation – Capitalises on breadth of experience – Builds scientific, medical and regulatory competence – Parallels FDA organisational approach – Builds opinion leader/investigator networks h Scientifically opportunistic h Innovation orientation h Lon
Slide 12: Therapy Area missions; high TA growth ambitions
Therapy Area missions Oncology CNS New treatments Delivering competitive brands that for major cancers meet important unmet medical needs in psychiatry and neurology Pain Infection Maintain leadership in Bring to market new antimicrobial anaesthesia and develop novel therapies avoiding cross- treatm
Slide 13: R&D Strategy: Building our future
A strong pipeline for tomorrow Diprivan® Seroquel® Arimidex® esomeprazole Losec® Nolvadex® Symbicort Casodex ® ® Accolate ® Tenormin® Oxis® superstatin Zoladex® thrombin Atacand® Pulmicort® Seloken® inhibitor Zomig ® Viozan™ Zestril® Xylocaine® Rhinocort® Iressa™ Faslodex™ ® Merrem Prilosec® Plendil
Slide 14: Slide 14